Pharmacy - Pharmacoeconomics News & Articles

481 An Economic Comparison of Three Cell Culture Techniques: Fed-Batch, Concentrated Fed-Batch, and Concentrated Perfusion Full Text BioPharm International, February 10, 2011

482 Registering New Drugs for Low-Income Countries: The African Challenge Full Text PLoS Medicine, February 9, 2011

483 The social and economic consequences of epilepsy: A controlled national study Full Text Epilepsia, February 8, 2011

484 High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions Full Text Annals of Internal Medicine, February 7, 2011

485 Cheaper RA medications may be similar to biologics in slowing radiographic progression of RA Full Text American Pharmacists Association News, February 4, 2011    Evidence Based Medicine

486 Cost of acute ischemic and hemorrhagic stroke in Turkey Clinical Neurology and Neurosurgery, February 4, 2011

487 Effect of Medicare Part D and insurance type on Medicare beneficiary access to prescription medication and use of prescription cost-saving measures Journal of the American Pharmacists Association, February 3, 2011

488 Hypothetical Intertemporal Choice and Real Economic Behavior: Delay Discounting Predicts Voucher Redemptions During Contingency-Management Procedures Experimental and Clinical Psychopharmacology, February 3, 2011

489 Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis American Journal of Cardiovascular Drugs, February 2, 2011

490 Cost-effectiveness of Outpatient Management for Febrile Neutropenia in Children With Cancer Full Text Pediatrics, February 2, 2011

491 Compliance, Persistence, Healthcare Resource Use, and Treatment Costs Associated with Aliskiren plus ARB versus ACE Inhibitor plus ARB Combination Therapy: In US Patients with Hypertension American Journal of Cardiovascular Drugs, February 2, 2011    Clinical Article

492 Cost burden of second fracture in the US Health System Bone, January 27, 2011

493 New Parkinson's disease pipeline needs to offer improved quality of life, balanced with cost containment Full Text Formulary , January 27, 2011

494 Study proves that even with increased drug costs, adherence will reduce overall health spending Full Text Drug Topics, January 26, 2011

495 A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice PharmacoEconomics, January 24, 2011

496 Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest PharmacoEconomics, January 24, 2011

497 A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada PharmacoEconomics, January 24, 2011    Evidence Based Medicine

498 Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration PharmacoEconomics, January 24, 2011

499 Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis PharmacoEconomics, January 24, 2011

500 Patient Characteristics and Medical Care Costs Associated With Hypertriglyceridemia The American Journal of Cardiology, January 21, 2011

1 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement Clinical Therapeutics, April 18, 2013    Review Article

2 The Economic Burden of Treatment-Resistant Depression Clinical Therapeutics, April 19, 2013

3 Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact Journal of Clinical Pharmacy and Therapeutics, April 10, 2013    Review Article

4 Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US Annals of Pharmacotherapy, April 22, 2013    Review Article

5 Role of the Pharmacist in Achieving Performance Measures to Improve the Prevention and Treatment of Venous Thromboembolism Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 9, 2013

6 A systematic review and meta-analysis of pharmacist-led fee-for-services medication review British Journal of Clinical Pharmacology, April 24, 2013    Evidence Based Medicine    Review Article

7 Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation Clinical Cardiology, March 18, 2013    Free full text

8 Cost-effectiveness of deep brain stimulation in patients with Parkinsons disease Movement Disorders, April 29, 2013

9 Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany Clinical Research in Cardiology, March 27, 2013

10 Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer Annals of Oncology, March 26, 2013

11 The Cost-Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 29, 2013

12 Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial Vaccine , March 20, 2013

13 Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013 American Journal of Health-System Pharmacy, March 13, 2013    Review Article

14 Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies Bone Marrow Transplantation, April 16, 2013

15 Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations- A simulation of comparative cost-effectiveness British Journal of Cancer, April 15, 2013    Review Article

16 Systematic Review and Quality Assessment of Cost-Effectiveness Analysis of Pharmaceutical Therapies for Advanced Colorectal Cancer Annals of Pharmacotherapy, April 8, 2013    Evidence Based Medicine    Review Article

17 Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer Colorectal Disease, April 2, 2013

18 The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions Multiple Sclerosis Journal, April 22, 2009

19 Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom Clinical Therapeutics, March 26, 2013

20 Outcomes, Health Costs and Use of Antiplatelet Agents in 7,082 Patients Admitted for an Acute Coronary Syndrome Occurring in a Large Community Setting Cardiovascular Drugs and Therapy, March 28, 2013